Monofer® launched in Germany

October 25, 2011

Pharmacosmos A/S, Denmark, announced today the launch of the company's product Monofer® in Germany. The Danish company has entered into collaboration with Medice Pharma GmbH & Co. in Iserlohn, Germany.

The German company is responsible for the marketing of Monofer® in Germany and joins Pharmacosmos' line of trusted partners. 

Lars Christensen, MD, President and CEO of Pharmacosmos, said: "We are delighted to team up with Medice as our partner for Monofer® in Germany and we look forward to the collaboration. Medice is a highly professional company specialized in the treatment of anaemia." 

Richard Ammer, MD, PhD, General Manager of Medice, said: "Patients suffering from iron deficiency anaemia will benefit from fast high dose therapy, which will result in fewer hospital visits for patients. Monofer® offers high dose opportunities in a single administration and we believe Monofer® will become a very important product in the treatment of iron deficiency anaemia in Germany."

Monofer® (iron isomaltoside 1000) is an intravenous iron compound based on an innovative chemical structure. Monofer® is indicated for treatment of iron deficiency anaemia and offers high dose administration up to 20mg/kg in 15-60 minutes. Monofer® offers most patients a full iron correction in just one visit and no test dose is required. Iron deficiency anaemia is a global health problem and Monofer® has the potential to cure millions of patients world-wide. 

Monofer® is registered in several countries and is currently available in UK, Ireland, Denmark, Sweden, Norway, Finland, Netherlands, Germany and Poland.

Further information
Lars Christensen, MDPresident and CEO
T: +45 59 48 59 59

Richard Ammer, MD, PhDGeneral Manager
T: +49 2371 937-0

About Medice Pharma GmbH & Co.
Medice is based in Iserlohn, Germany, and is a fully-integrated, mid-sized family-owned pharmaceutical enterprise. The company develops, manufactures and distributes high-quality drugs, pharmaceutical products and medical devices throughout Germany, Europe and key international markets and holds leading positions in defined niche indications. Likewise, Medice has a broad portfolio for patients with renal insufficiency and is the first supplier with Epoetin and iron to treat anemia.

About Pharmacosmos A/S

Pharmacosmos develops and markets medicines for the treatment of iron deficiency. A research-based company, its ongoing R&D programme focuses on improving the treatment options for healthcare professionals, patients suffering from iron deficiency and veterinary treatments. .

Pharmacosmos is a family-owned Danish company and operates in more than 60 countries across Europe, the Americas and Asia. Its facilities are approved by both the Danish Medicines Agency and the US Food & Drug Administration, FDA.